Core Viewpoint - The SHS Innovation Drug Index has shown significant growth, reflecting the performance of listed companies involved in innovative drug research and production in both mainland China and Hong Kong [1]. Group 1: Index Performance - The SHS Innovation Drug Index rose by 1.82%, closing at 2501.58 points, with a trading volume of 59.01 billion yuan [1]. - Over the past month, the index has increased by 10.57%, and over the last three months, it has surged by 34.82%. Year-to-date, the index has gained 57.90% [1]. Group 2: Index Composition and Adjustments - The index is composed of up to 50 representative securities selected from mainland and Hong Kong listed companies engaged in innovative drug development and production, ranked by market capitalization [1]. - The index is adjusted semi-annually, with changes implemented on the next trading day following the second Friday of June and December each year. Weight factors are generally fixed until the next adjustment [1]. - In special circumstances, the index may undergo temporary adjustments, such as when a sample company is delisted or undergoes mergers, acquisitions, or splits [1].

Core Viewpoint - The increasing popularity of A-shares has led many public fund managers to open real-time trading accounts on online platforms to showcase their performance [1][2]. Group 1: Fund Managers Opening Real Accounts - Numerous public fund managers, including those from Guojin Fund and Guotai Fund, have opened real accounts on platforms like Tiantian Fund and Ant Wealth [2][10]. - The total amount of these real accounts is generally high, with some exceeding 4 million yuan, such as Guojin Fund's Yao Jiahong, whose account reached 4.1394 million yuan [11]. Group 2: Performance and Investment Choices - Some fund managers have reported holding profits exceeding 1 million yuan, indicating positive returns [3][13]. - Fund managers predominantly invest in their own products or those from their fund companies, with no evidence of investing in products from other companies [8][9]. Group 3: Comparison with Retail Investors - Despite the reported profits, fund managers' returns often lag behind those of ordinary investors, with the top retail investors achieving monthly returns between 30.41% and 39.39% [16][17]. - Over the past year, no fund manager has made it to the top performance rankings, which raises questions about their short-term investment capabilities compared to retail investors [18][19]. Group 4: Implications and Industry Perspectives - The practice of fund managers opening real accounts may enhance trust and transparency with investors, especially for smaller firms or emerging managers [22][23]. - However, there are concerns that these accounts primarily serve as a marketing tool for their own products rather than providing genuine investment insights [12][21][26].

Core Viewpoint - The trend of "showing real accounts" among fund managers is becoming a new competition, reflecting increased industry transparency, upgraded investor professionalism, and a transformation in marketing models [1][6]. Group 1: Fund Manager Performance - Several fund managers have reported substantial real account gains, with notable examples including Yao Jiahong from Guojin Fund achieving a cumulative profit of 1.1336 million yuan on an investment of 4.139 million yuan, and Ma Fang from Guojin Fund with a profit of 627,765 yuan on an investment of 1.982 million yuan [3][4]. - Other fund managers like Zhang Lu and Ren Jie from Yongying Fund have also seen significant returns, with Ren Jie achieving a return rate close to 120% on an investment of 295,400 yuan [4][6]. Group 2: Industry Trends - The practice of "showing real accounts" is enhancing communication between fund managers and investors, allowing for more immediate and interactive exchanges regarding investment strategies and market conditions [6][7]. - Analysts believe that this trend helps break down information asymmetry, allowing investors to better understand fund managers' strategies and performance, thus fostering a more informed investment environment [6][7]. Group 3: Market Insights - Fund managers are addressing investor concerns about market conditions, particularly regarding the recent highs in indices, attributing these movements to ample liquidity and supportive government policies [6][7]. - The shift in market sentiment is seen as a response to the previous two years of pessimism, with expectations that the transition to new economic drivers will occur more rapidly than anticipated [7].

Core Viewpoint - The SHS Innovation Drug Index has shown significant growth, reflecting the performance of listed companies involved in innovative drug research and production in both mainland China and Hong Kong [1]. Group 1: Index Performance - The SHS Innovation Drug Index increased by 4.03%, reaching 2393.56 points, with a trading volume of 54.435 billion [1]. - Over the past month, the index has risen by 11.98%, and over the last three months, it has increased by 35.45%. Year-to-date, the index has surged by 47.88% [1]. Group 2: Index Composition and Adjustments - The index is composed of up to 50 representative securities selected from mainland and Hong Kong markets, focusing on companies engaged in innovative drug development and production [1]. - The index is adjusted semi-annually, with changes implemented on the next trading day following the second Friday of June and December each year. Weight factors are generally fixed until the next adjustment [1]. - In special circumstances, the index may undergo temporary adjustments, such as when a sample company is delisted or undergoes mergers, acquisitions, or splits [1].

Core Insights - The trend of fund managers showcasing their real-time trading accounts on platforms like Ant Fund and Tian Tian Fund is gaining traction among investors, with over 20 fund managers publicly sharing their holdings and operations [2][3] - Fund manager Yao Jiahong from Guojin Fund leads with a real account amount of 4.064 million yuan, primarily investing in two quantitative funds with a total holding return of 1.058 million yuan [2][5] - Some fund managers are experiencing losses, such as Li Zhaoyu from Founder Fubon Fund, whose real account totals approximately 104,600 yuan with a cumulative loss of 1,062.77 yuan [2][8] Fund Manager Performance - As of August 5, five fund managers have real account sizes exceeding 1 million yuan, with Yao Jiahong at the forefront with 4.064 million yuan [3][5] - Yao Jiahong's holdings include approximately 2.72 million yuan in Guojin Quantitative Multi-Factor A with a return rate of 35.39% and about 1.35 million yuan in Guojin Quantitative Multi-Strategy A with a return rate of 34.84% [5] - Another fund manager, Ma Fang from Guojin Fund, has a total real account amount of 1.947 million yuan with a cumulative return of 592,000 yuan [5] Market Trends and Strategies - The A-share market has shown fluctuations, with the Shanghai Composite Index rebounding above 3,600 points, marking a new high for the year [9] - Fund managers like Cheng Xi from E Fund view recent market corrections as normal, suggesting investors should focus on long-term holdings rather than short-term volatility [10] - Investment opportunities in sectors such as technology growth, Chinese manufacturing, and new consumption are highlighted as areas of potential growth [11]

Group 1 - The core viewpoint of the article highlights the performance of the CSI Hong Kong-Shanghai Innovative Drug Industry Index, which rose by 2.51% to 1955.39 points, with a trading volume of 33.441 billion yuan [1] - The index has shown significant growth, increasing by 6.55% over the past month, 12.29% over the past three months, and 22.60% year-to-date [1] - The index is composed of up to 50 representative securities from the mainland and Hong Kong markets, focusing on companies involved in innovative drug research and production, reflecting the overall performance of the innovative drug industry [1] Group 2 - The index is adjusted semi-annually, with changes implemented on the next trading day following the second Friday of June and December each year [1] - Weight factors are generally fixed until the next scheduled adjustment, with special circumstances allowing for temporary adjustments [1] - The index will be modified if a sample company is delisted or if there are significant corporate changes such as mergers or acquisitions [1] Group 3 - Public funds tracking the SHS Innovative Drug Index include various ETFs and fund products from companies like Guotai, Xizang Dongcai, and Huatai Bairui [2]